528 material Form 8-K filings that 462 companies we cover made with the SEC in January 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Air Products said preliminary fiscal first-quarter 2025 GAAP EPS was $2.77 and adjusted EPS was $2.86, with adjusted EPS above the top of its prior $2.75 to $2.85 guidance range. The figures are preliminary and subject to change because quarter-end close processes are not complete, and the company will release full results on February 6, 2025. Shareholders get an early read on a quarter that beat the company's own guidance, though both GAAP and adjusted EPS rose only about 1% from the prior year.
Preliminary Q1 FY25 GAAP EPS of $2.77, up from $2.73 a year earlier (about 1%)
Preliminary adjusted EPS of $2.86, up from $2.82 a year earlier, versus prior guidance of $2.75 to $2.85
Adjusted EPS excludes $0.10 per share in shareholder activism costs tied to a proxy contest led by Mantle Ridge L.P., and a $0.05 per share gain on de-designated cash flow hedges
Full Q1 FY25 results to be released before market open on February 6, 2025
Vericel released preliminary, unaudited results for 2024, projecting total net revenue of about $237 million to $237.5 million, up 20%, and GAAP net income for the full year. It also issued 2025 guidance calling for 20% to 23% revenue growth and raised its mid-term gross margin and adjusted EBITDA margin targets. Shareholders should note that the company says the final audited figures may differ materially from these estimates.
Full-year 2024 total net revenue expected at about $237 million to $237.5 million, up 20%; full-year GAAP net income positive
Fourth-quarter 2024 revenue expected at $75.2 million to $75.7 million; GAAP net income expected at $17.5 million to $18.5 million
2025 guidance: 20% to 23% revenue growth, gross margin of 73% to 74%, adjusted EBITDA margin of 25% to 26%
About $167 million in cash, restricted cash and investments and no debt as of December 31, 2024; figures are preliminary and unaudited
Sotera Health said preliminary full-year 2024 revenue is approximately $1.1 billion, growth of nearly 5% over 2023 and more than 5% on a constant currency basis. The company said the figure is within the revenue guidance it gave with its third-quarter 2024 results, but it remains subject to year-end closing procedures and audit, so final results may differ materially.
Preliminary full-year 2024 revenue of approximately $1.1 billion, up nearly 5% versus 2023 and more than 5% on a constant currency basis
Revenue range is within the guidance given at the third-quarter 2024 earnings release
Chairman and CEO Michael B. Petras, Jr. presents a business update at the J.P. Morgan Healthcare Conference on January 14, 2025 at 11:15 a.m. Eastern Time
Full 2024 results and 2025 outlook are scheduled for release on February 27, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.